SIGNATORIES, as of 23 June 2008


1. Ms. Paula Akugizibwe, AIDS and Rights Alliance for Southern Africa, Namibia
2. Mr. Sidney Atwood, Brigham and Women’s Hospital, USA
3. Dr. Jaime Bayona, Socios En Salud-Sucursal Peru, Peru
4. Dr. Mercedes Becerra, Harvard Medical School, USA
5. Dr. Cesar Bonilla, National Health Strategy for TB Prevention and Control, Peru
6. Dr. Maryline Bonnet, Epicentre / Médecins Sans Frontières, Switzerland
7. Dr. William Burman, Denver Public Health, USA
8. Dr. Peter Cegielski, U.S. Centers for Disease Control and Prevention, USA
9. Dr. Richard Chaisson, Johns Hopkins University School of Medicine, USA
10. Dr. Frank Cobelens, KNCV Tuberculosis Foundation, The Netherlands
11. Dr. Theodore Cohen, Brigham and Women’s Hospital, USA
12. Dr. Margareth Dalcolmo, Centro de Referência Prof. Hélio Fraga, Brazil
13. Dr. Charles Daley, National Jewish Medical and Research Center, USA
14. Dr. Manfred Danilovits, Tartu University Lung Clinic, National Tuberculosis Program, Estonia
15. Mr. Karel De Beule, Tibotec, Belgium
16. Dr. Victor De Gruttola, Harvard School of Public Health, USA
17. Dr. Mary Ann DeGroote, Colorado State University, USA
18. Dr. Ashwin Dharmadhikari, Brigham & Women’s Hospital, USA
19. Ms. Nancy Dianis, Westat, USA
20. Dr. Kelly Dooley, Johns Hopkins University School of Medicine, USA
21. Dr. Kathleen Eisenach, University of Arkansas for Medical Sciences, USA
22. Dr. Gerald Friedland, Yale University School of Medicine, USA
23. Dr. Robert Gerety, Medicine in Need, USA
24. Dr. Abdul Hamid Salim, Damien Foundation, Bangladesh
25. Mr. Mark Harrington, Treatment Action Group, USA
26. Dr. Martin Hirsch, Harvard Medical School, USA
27. Dr. Timothy Holtz, U.S. Centers for Disease Control and Prevention, USA
28. Dr. Robert Horsburgh, Boston University School of Public Health, USA
29. Dr. Gary Horwith, Sequella, Inc., USA
30. Dr. Frauke Jochims, Médecins Sans Frontières, Switzerland
31. Dr. Salmaan Keshavjee, Harvard Medical School, USA
32. Dr. Michael Kimerling, University of Alabama at Birmingham School of Medicine, USA
33. Dr. Kitty Lambregts, KNCV Tuberculosis Foundation, The Netherlands, and MDR-TB Working Group of the Stop TB Partnership, Switzerland
34. Dr. Vaira Leimane, State Centre of Tuberculosis and Lung Diseases, Latvia
35. Dr. Christian Lienhardt, International Union Against Tuberculosis and Lung Disease, France
36. Dr. Pushpa Malla, National Tuberculosis Centre, National Tuberculosis Program, Nepal
37. Dr. William Mac Kenzie, U.S. Centers for Disease Control and Prevention, USA
38. Dr. Charles Mgone, European and Developing Countries Clinical Trials Partnership, Netherlands
39. Dr. Fuad Mirzayev, World Health Organization, Switzerland
40. Prof. Denis Mitchison, St. George’s Hospital, UK
41. Dr. Carole Mitnick, Harvard Medical School, USA
42. Dr. Edward Nardell, Brigham and Women’s Hospital, USA
43. Dr. Eric Nuermberger, Johns Hopkins University School of Medicine, USA
44. Mrs. Carol Nyirenda, Treatment Advocacy and Literacy Campaign, Zambia
45. Dr. Thomas Nyirenda, European and Developing Countries Clinical Trials Partnership, South Africa
46. Ms. Lesley Odendal, Treatment Action Campaign, South Africa
47. Dr. Charles Peloquin, National Jewish Medical and Research Center, USA
48. Dr. Sergey Popov, Russia Moscow Medical Academy, Russia
49. Dr. Alexander Pym, Medical Research Council of South Africa, South Africa.
50. Dr. Lee Reichman, University of Medicine and Dentistry of New Jersey, USA
51. Dr. Hind Satti, Partners In Health, Lesotho
52. Dr. Rajeswari Ramachandran, Tuberculosis Research Centre, India
53. Dr. Jussi Saukkonen, Boston University School of Medicine, USA
54. Dr. Neil Schluger, Columbia University Medical Center, USA
55. Dr. Kwonjune Seung, Brigham and Women’s Hospital, USA
56. Dr. Alexander Sloutsky, Massachusetts State Laboratory Institute, USA
57. Dr. Thelma Tupasi, Tropical Disease Foundation, Philippines
58. Dr. Frank van Leth, KNCV Tuberculosis Foundation, The Netherlands
59. Mr. Wim Vandevelde, European AIDS Treatment Group, Belgium
60. Dr. Francis Varaine, Médecins Sans Frontières, France
61. Dr. Andrew Vernon, U.S. Centers for Disease Control and Prevention, USA
62. Dr. Tido von Schoen-Angerer, Médecins Sans Frontières, Switzerland
63. Dr. Charles Wells, Otsuka America Pharmaceutical, Inc., USA
64. Dr. Matteo Zignol, World Health Organization, Switzerland

65. Dr. Elijah Amooti, African Eye Trust, England
66. Dr. Renuka Babu, Medicine in Need, USA
67. Dr. Nulda Beyers, Desmond Tutu TB Centre, South Africa
68. Dr. Jose A. Caminero, International Union against Tuberculosis and Lung Disease, France
69. Dr. Anne Donnelly, Project Inform, USA
70. Dr. Tine De Marez, Tibotec, Inc., USA
71. Dr. Ann Ginsberg, Global Alliance for TB Drug Development, USA
72. Dr. Howard Grossman, Fenway Community Health, USA
73. Dr. Serena Koenig, Brigham and Women’s Hospital, USA
74. Dr. Helen McIlleron, University of Cape Town, South Africa
75. Dr. Francisco Rosas, Vivir. Participación, Incidencia, y Transparencia, A.C., Mexico
76. Dr. Leonard Sacks, U.S. Food and Drug Administration, USA
77. Dr. Diana Weil, World Health Organization, Switzerland
78. Dr. Mette Klouman, The Norwegian Heart and Lung Patient Organisation, Norway

Dear GHDonline members and visitors,

If you wish to sign the Cambridge Declaration, please add your name to this list by clicking on "reply." In addition, if you'd like to join protocol-writing groups and become a member of RESIST-TB, the private community of practice available on GHDonline for stakeholders collaborating to improve and expand DR TB clinical trials, please contact: .

If you are not a member of GHDonline but would like to sign the Cambridge Declaration, please click on "Join" and add "DR TB" in your subject line. As soon as you receive a confirmation of membership, you will be able to proceed as detailed above.

The DR TB Clinical Trials Working Group, or RESIST-TB, was created in June 2008 by stakeholders from communities, NGOs, governments, donors, industry, and academia to:

- conduct priority clinical trials that test strategies in adults and children:
> to shorten and improve treatment for drug-resistant TB, and
> to prevent drug-resistant TB

- mobilize the resources needed for these trials

- build the capacity of trial sites

- report to stakeholders on progress made, and

- ensure that these efforts complement those of other groups, and address the critical unmet needs outlined above.

Prof. Simon Schaaf, University of Stellenbosch, South Africa

Dr. David Moore, Imperial College London, UK

Maxine Caws

Maxine Caws, Oxford University Clinical Research Unit, Vietnam

Susan van den Hof, KNCV Tuberculosis Foundation, The Netherlands

Kelly Stinson, Otsuka America Pharmaceutical, Inc., USA